Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics Price Performance
Shares of CLDX Stock traded up $2.80 during trading hours on Friday, hitting $37.33. 582,593 shares of the company's stock were exchanged, compared to its average volume of 563,335. Celldex Therapeutics has a 52 week low of $19.85 and a 52 week high of $57.20. The stock's 50-day moving average is $27.91 and its 200-day moving average is $30.11.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. SVB Leerink cut their price objective on Celldex Therapeutics from $68.00 to $64.00 and set an "outperform" rating for the company in a report on Tuesday. HC Wainwright boosted their price target on shares of Celldex Therapeutics from $60.00 to $73.00 and gave the company a "buy" rating in a research report on Friday, July 1st.